Please login to the form below

Not currently logged in
Email:
Password:

MSD submits sarcoma drug for US approval

MSD has asked the US Food and Drug Administration to consider its oral mTOR inhibitor, ridaforolimus, for approval in the treatment of sarcomas – a cancer of the body's connective tissue

MSD has asked the US Food and Drug Administration (FDA) to consider its oral mTOR inhibitor, ridaforolimus, for approval in the treatment of patients with metastatic soft tissue or bone sarcomas in patients who had a favourable response to chemotherapy.

The therapy has already been submitted to the European Medicines Agency (EMA) for approval.

Sarcomas are a group of cancers of connective tissue of the body for which there are currently limited treatment options.

MSD obtained full rights to ridaforolimus in May 2010 in an agreement with its initial developers, ARIAD Pharmaceuticals, for an upfront payment of $50m plus additional milestone payments.

ARIAD agreed to co-promote the drug in the US if it is approved.

6th October 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Healthcircle

We're Healthcircle – an award-winning healthcare advertising and creative communications agency, offering a holistic approach to brand health. With a...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics